FDA approves Medtronic's Marquis ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale the first product in Medtronic's new generation of implantable cardioverter defibrillators (ICDs). The Marquis DR dual-chamber ICD offers a charge time of just 7.5 seconds - ie the time needed before the device delivers a life-saving therapy after an abnormal heart rhythm is detected. The 36cc product also incorporates a battery that can last 7-8 years, resulting in less frequent device replacement for the patient. The device is being launched in the US, Canada and Europe, says the firm.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.